Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunction of daptomycin for the treatment of pneumococcal meningitis
2017-002888-18Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Jul 2017
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of daptomycin in pneumococcal meningitis (2 arms), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoint: Disability-free survival at Day 30. Started Jul 2017; status: completed.
02
Drugs
daptomycin
03
Conditions
pneumococcal meningitis
Beyond the preview
Go deeper on 2017-002888-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002888-18.